Vernalis PLC Share News (VER)

N+1 Singer remains upbeat on Vernalis

Broker N+1 Singer reiterated buy on biotech specialist Vernalis after the group hailed the successful completion of a final comparative bioavailability study for CCP-01, its promising long-acting prescription cough cold medicine for the US market. N+1 Singer Analyst, Dr Jens Lindqvist, said that t

Wednesday broker round-up UPDATE

African Barrick Gold: Canaccord Genuity ups target price from 180p to 205p keeping a hold recommendation. Antofagasta: Westhouse Securities takes target price from 1000p to 1060p and maintains its buy recommendation. BG Group: Liberum Capital reduces target price from 1475p to 1280p downgrading to

STOCKS NEWS EUROPE-UK small caps index rises to beat blue-chips

The FTSE Small Caps Index closes 0.1 percent higher, outperforming a 0.9 percent fall on the blue-chip FTSE 100 index and a flat performance on the FTSE 250 mid-caps index. The junior-listed FTSE AIM All Share index also finishes 0.1 percent higher. Manroy rallies 34.8 percent after t

AIM IN BRIEF: UBC Media Confirms Agreement To Acquire 7digital

STOCKS NEWS EUROPE-UK small caps edge higher

UK small caps firm 0.1 percent in early deals, in line with the blue chips, while junior-listed AIM shares advance 0.2 percent. Drug firm Vernalis climbs 8.4 percent after the company reports first-half revenue up 29 percent to 7.6 million pounds. Peel Hunt keeps its "buy" rating on V

Advanced Oncotherapy CEO makes triple purchase

The Chief Executive of Advanced Oncotherapy, a provider of new technology for innovative and patient-focused cancer treatments, has this week purchased three lots of shares in the group, taking his stake to just under 69.4m shares. On Thursday Sinclair purchased one round of 8.075m shares at 1.59p

Polymetal International Chief buys 100,000 shares

The Chief Executive Officer of Polymetal International has purchased 713,750 pounds-worth of shares, just two days after the FTSE 100 mining group reported that the Mayskoye mine in Russia had produced its first dry gold concentrate. Vitaly Nesis celebrated the news with the purchase of 100,000 sh

Vernalis receives 1.5m dollar payment through Genentech collaboration

AIM-listed pharmaceuticals company Vernalis has received a 1.5m dollar payment under its drug discovery collaboration with Genentech, a member of the Roche group. The collaboration, which commenced in January 2012, aims to discover novel small molecules against an undisclosed target utilising Vern

Vernalis announces positive results for Parkinson's disease treatment study

AIM-listed pharmaceutical company Vernalis has published positive results for a study of potential applications for Parkinson's disease and other central nervous system indications. The study examined the effects of V81444, its "A2A antagonist", on brain function. The study demonstrated that full

Vernalis's first half revenues jump

Vernalis, a development stage pharmaceutical company, saw first half losses halve on the back of a sharp rise in revenues, driven by a significant increase in collaboration income. Loss for the period was slashed to £3.2m (2011: £7.0m) on revenues of £5.9m, up 365 from £4.3m for the same period the

Vernalis up as Parkinson's drug passes safety trial

The drug development firm Vernalis has reported a successful outcome in Phase I trials of its V81444 treatment that may be useful in the fight against Parkinson's disease. The double-blind, placebo-controlled study showed "a wide range of doses were found to be well tolerated with no unexpected saf

Wednesday tips round-up: Ryanair, LSE, Vernalis

Questor, in the Telegraph, gives some quite clear advice on Ryanair: sell. The shares have risen 78% since the first tip back in 2009 and the oil price could make things difficult for the airlines in 2012. Time to get out and take profits, the paper recommends. In the Times, Tempus likes the Lond

Market backs transformational Vernalis deal

Shares in Vernalis, a UK pharmaceuticals company, were marked up after the company said it has placed shares at a premium to fund a drug development programme in combination with privately held US firm Tris Pharma. The company has placed 50m new shares, representing around 50% of the existing share

Vernalis pleased with tests on new drug

Shares in Vernalis rose this morning after the pharmaceutical firm said tests on its new painkiller had so far proved successful. The firm said that its Phase 1 trial of 'V158866' - a 'fatty acid amide hydrolase inhibitor' - had seen positive results following studies on male volunteers, pushing sh

Sector movers: Falling metals prices pressures mining sector lower

The miners are on the decline Tuesday, helped lower by the falling metals prices. Copper and gold futures have fallen as the escalating crisis in Japan has bought about concerns over demand. Mining titans Kazakhmys, Eurasian Natural Resources Corp, Anglo American, Antofagasta and Fresnillo are all